Fredun Pharmaceuticals Limited announced its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026, on May 25, 2026. The company reported strong financial performance with substantial growth in revenue, profitability, and operating margins across both the full year and the fourth quarter. The Board of Directors recommended a final dividend of ₹0.70 per equity share and approved a 2:1 bonus issue, signaling confidence in future growth.

Financial Performance

For the fiscal year 2025-26, the company reported a standalone net profit of ₹33.21 crore, compared to ₹20.81 crore in the previous year. Total income from operations rose to ₹639.12 crore from ₹456.27 crore in the prior year. The fourth quarter also reflected robust year-on-year growth, with net profit climbing to ₹11.07 crore from ₹7.07 crore in the same period of the previous year. Quarterly revenue grew to ₹213.05 crore compared to ₹167.41 crore in the corresponding prior-year period.

Key Financial Metrics

The following table summarizes the standalone financial performance for the year ended March 31, 2026, alongside the quarterly comparison:

Operating Performance

The company's quarterly operating performance showed a marked improvement, with Q4 EBITDA rising to ₹29.13 crore from ₹17.44 crore in the same period of the previous year. The EBITDA margin expanded significantly to 13.67% from 10.42% year-on-year, reflecting improved operational efficiency and better cost management during the quarter.

Board Decisions

The Board of Directors recommended a final dividend of ₹0.70 per equity share for the financial year 2025-26. This dividend is subject to shareholder approval at the ensuing Annual General Meeting. Additionally, the board approved the issuance of bonus shares to shareholders and warrant holders in the ratio of 2:1, meaning shareholders will receive two fully paid-up bonus equity shares of ₹10 each for every one existing equity share held. The record date for determining eligibility will be intimated in due course.

Corporate Actions

In other corporate decisions, the board approved an increase in the authorized share capital from ₹10 crore to ₹50 crore, subject to shareholder approval. The company also appointed M/s. Nikhil Maniar & Associates as Internal Auditor and M/s. Joshi Apte & Associates as Cost Auditor for the financial year 2026-2027. The statutory auditors issued an unmodified opinion on the standalone and consolidated financial results.

Fredun Pharmaceuticals Limited announced on May 15, 2026, the launch of 'DAULCÉL', its premium wellness and longevity-focused brand developed to cater to the growing demand for preventive healthcare, healthy aging, and lifestyle-oriented wellness solutions. The launch marks a strategic step in the company's expansion into innovation-led and future-focused healthcare segments, leveraging its existing formulation and healthcare expertise.

Brand Overview and Strategic Positioning

DAULCÉL is positioned as a premium wellness platform centered on quality, innovation, and evolving consumer wellness needs. The brand addresses the increasing global focus on vitality, wellness optimization, recovery-focused healthcare, and long-term healthy living through science-oriented wellness solutions. The initiative complements Fredun Pharmaceuticals' existing pharmaceutical and healthcare capabilities while creating new opportunities within specialized wellness and longevity-driven categories.

The following table outlines the key parameters of the DAULCÉL brand launch:

Key Highlights of the Launch

The DAULCÉL brand launch encompasses several strategic dimensions:

• First premium NAD+ based wellness offerings introduced in India's emerging longevity and cellular wellness segment
• Strategic expansion into preventive and lifestyle-oriented healthcare
• Focused on wellness, vitality, and healthy aging solutions
• Science-oriented and innovation-driven brand approach
• Expansion into emerging and high-growth wellness categories
• Strengthening Fredun's specialty healthcare and wellness portfolio
• Leveraging the company's formulation and healthcare expertise
• Focused on differentiated, quality-driven wellness offerings

DAULCÉL's initial portfolio is designed around premium wellness solutions aligned with the growing demand for advanced wellness, cellular vitality, and healthy lifestyle management. The brand aims to combine innovation, quality-focused development, and consumer-centric healthcare experiences to establish a differentiated presence within the evolving wellness market.

Management Commentary

Commenting on the development, Mr. Fredun Medhora, Managing Director, said: "Daulcé reflects our focus on building future ready healthcare capabilities. Preventive health and longevity are becoming increasingly relevant, and we see strong potential in delivering science driven solutions that address these needs in a meaningful way."

About Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited is a healthcare and pharmaceuticals company offering a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs), and narcotics. The company is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products, along with animal healthcare products. It primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America.

The company's financial performance for FY25 is summarised below: